BLLN — BillionToOne, Inc.

Summary of BillionToOne Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $96.1 million, up 113% year-over-year (YoY).
• Full Year 2025 Revenue: $305.1 million, a 100% increase from $152.6 million in 2024.
• Gross Margin: 71.4% in Q4, up from 57% YoY; full-year gross margin at 70%.
• Operating Income: $10.3 million in Q4, compared to an operating loss of $11.7 million in Q4 2024; full-year operating income of $16 million.
• Net Income: $4.4 million ($0.11 per diluted share) in Q4, versus a net loss of $11.5 million in Q4 2024.
• Adjusted EBITDA Margin: 19% in Q4 and 13% for the full year.
• Cash Position: Ended Q4 with $496 million in cash and $50 million in term debt.

2. Strategic Updates and Business Highlights

• Product Launches: Introduced several new products, including expanded Fetal Antigen NIPT and Northstar PGx for pharmacogenomics.
• Market Access: Secured Medicare coverage for Northstar Select and signed contracts with 44 payers, covering 250 million lives.
• Sales Growth: Test volumes increased by 51% YoY, with a significant boost in both prenatal (98% YoY) and oncology (736% YoY) revenues.
• Sales Force Expansion: Plans to grow the sales team from 150 to 185 in prenatal and from 45 to 65 in oncology by year-end 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Increased to $430 million to $445 million, representing 41% to 46% growth compared to 2025.
• Profitability: Expected to maintain positive GAAP operating income for 2026.
• Growth Drivers: Anticipated continued momentum in prenatal and oncology segments, with additional growth from new health system integrations and expanded payer contracts.

4. Bad News, Challenges, or Points of Concern

• Competition: Increased competition in therapy selection and response monitoring, although BillionToOne has not seen significant negative impact from competitors thus far.
• Operational Challenges: The need for EMR integration with health systems may delay some growth opportunities.
• Cost Management: While COGS per test decreased, higher stock-based compensation expenses were noted, which may impact future margins.
• Market Awareness: Approximately 50% of providers are still unaware of the UNITY product, indicating a need for increased marketing efforts.

5. Notable Q&A Insights

• Provider Awareness: CEO Oguzhan Atay highlighted that around 50% of providers do not know about UNITY, suggesting significant growth potential as awareness increases.
• Health System Engagement: Discussions with maternal-fetal medicine specialists (MFMs) are crucial for driving adoption of tests in health systems.
• Sales Metrics: The increase in active ordering providers in Q4 is expected to lead to strong test volume growth in Q1 2026.
• In-Network Contracting: The new in-network contract with UnitedHealthcare is anticipated to enhance ASPs rather than decrease them, contrary to typical expectations in the industry.

This summary captures the essential financial performance, strategic initiatives, future outlook, and challenges faced by BillionToOne, along with key insights from the Q&A session that provide additional context to the company's operations and market positioning.